Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab

Laura Pizzuti, Domenico Sergi, Isabella Sperduti, Luigi Di Lauro, Marco Mazzotta, Claudio Botti, Fiorentino Izzo, Luca Marchetti, Silverio Tomao, Paolo Marchetti, Clara Natoli, Antonino Grassadonia, Teresa Gamucci, Lucia Mentuccia, Emanuela Magnolfi, Angela Vaccaro, Alessandra Cassano, Ernesto Rossi, Andrea Botticelli, Valentina Sini & 13 others Maria G. Sarobba, Maria Agnese Fabbri, Luca Moscetti, Antonio Astone, Andrea Michelotti, Claudia De Angelis, Ilaria Bertolini, Francesco Angelini, Gennaro Ciliberto, Marcello Maugeri-Saccà, Antonio Giordano, Maddalena Barba, Patrizia Vici

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The evidence emerged from the TOURANDOT trial encourages evaluating the role of anthropometric determinants on treatment outcomes in HER2-negative metastatic breast cancer patients treated with bevacizumab-including regimens. We thus analyzed data from a subgroup of these patients from a larger cohort previously assessed for treatment outcomes. Patients were included in the present analysis if body mass index values had been recorded at baseline. Clinical benefit rates, progression free survival and overall survival were assessed for the overall study population and subgroups defined upon molecular subtype. One hundred ninety six patients were included (N:196). Body mass index showed no impact on clinical benefit rates in the overall study sample and in the luminal cancer subset (p = 0.12 and p = 0.79, respectively), but did so in the triple negative subgroup, with higher rates in patients with body mass index ≥25 (p = 0.03). In the overall study sample, body mass index did no impact progression free or overall survival (p = 0.33 and p = 0.67, respectively). Conversely, in triple negative patients, progression free survival was significantly longer with body mass index ≥25 (6 vs 14 months, p = 0.04). In this subset, overall survival was more favorable (25 vs 19 months, p = 0.02). The impact of the molecular subtype was confirmed in multivariate models including the length of progression free survival, and number of metastatic sites (p < 0.0001). Further studies are warranted to confirm our findings in more adequately sized, ad hoc, prospective studies.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalCancer Biology and Therapy
DOIs
Publication statusAccepted/In press - Feb 9 2018

Fingerprint

Paclitaxel
Body Mass Index
Breast Neoplasms
Disease-Free Survival
Survival
Bevacizumab
Prospective Studies
Population
Neoplasms

Keywords

  • Bevacizumab-including regimens
  • BMI
  • first-line treatment
  • HER2-negative metastatic breast cancer
  • triple negative subtype

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. / Pizzuti, Laura; Sergi, Domenico; Sperduti, Isabella; Lauro, Luigi Di; Mazzotta, Marco; Botti, Claudio; Izzo, Fiorentino; Marchetti, Luca; Tomao, Silverio; Marchetti, Paolo; Natoli, Clara; Grassadonia, Antonino; Gamucci, Teresa; Mentuccia, Lucia; Magnolfi, Emanuela; Vaccaro, Angela; Cassano, Alessandra; Rossi, Ernesto; Botticelli, Andrea; Sini, Valentina; Sarobba, Maria G.; Fabbri, Maria Agnese; Moscetti, Luca; Astone, Antonio; Michelotti, Andrea; De Angelis, Claudia; Bertolini, Ilaria; Angelini, Francesco; Ciliberto, Gennaro; Maugeri-Saccà, Marcello; Giordano, Antonio; Barba, Maddalena; Vici, Patrizia.

In: Cancer Biology and Therapy, 09.02.2018, p. 1-7.

Research output: Contribution to journalArticle

Pizzuti, L, Sergi, D, Sperduti, I, Lauro, LD, Mazzotta, M, Botti, C, Izzo, F, Marchetti, L, Tomao, S, Marchetti, P, Natoli, C, Grassadonia, A, Gamucci, T, Mentuccia, L, Magnolfi, E, Vaccaro, A, Cassano, A, Rossi, E, Botticelli, A, Sini, V, Sarobba, MG, Fabbri, MA, Moscetti, L, Astone, A, Michelotti, A, De Angelis, C, Bertolini, I, Angelini, F, Ciliberto, G, Maugeri-Saccà, M, Giordano, A, Barba, M & Vici, P 2018, 'Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab', Cancer Biology and Therapy, pp. 1-7. https://doi.org/10.1080/15384047.2017.1416938
Pizzuti, Laura ; Sergi, Domenico ; Sperduti, Isabella ; Lauro, Luigi Di ; Mazzotta, Marco ; Botti, Claudio ; Izzo, Fiorentino ; Marchetti, Luca ; Tomao, Silverio ; Marchetti, Paolo ; Natoli, Clara ; Grassadonia, Antonino ; Gamucci, Teresa ; Mentuccia, Lucia ; Magnolfi, Emanuela ; Vaccaro, Angela ; Cassano, Alessandra ; Rossi, Ernesto ; Botticelli, Andrea ; Sini, Valentina ; Sarobba, Maria G. ; Fabbri, Maria Agnese ; Moscetti, Luca ; Astone, Antonio ; Michelotti, Andrea ; De Angelis, Claudia ; Bertolini, Ilaria ; Angelini, Francesco ; Ciliberto, Gennaro ; Maugeri-Saccà, Marcello ; Giordano, Antonio ; Barba, Maddalena ; Vici, Patrizia. / Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. In: Cancer Biology and Therapy. 2018 ; pp. 1-7.
@article{2236c7135df849449c75f45815ca55fe,
title = "Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab",
abstract = "The evidence emerged from the TOURANDOT trial encourages evaluating the role of anthropometric determinants on treatment outcomes in HER2-negative metastatic breast cancer patients treated with bevacizumab-including regimens. We thus analyzed data from a subgroup of these patients from a larger cohort previously assessed for treatment outcomes. Patients were included in the present analysis if body mass index values had been recorded at baseline. Clinical benefit rates, progression free survival and overall survival were assessed for the overall study population and subgroups defined upon molecular subtype. One hundred ninety six patients were included (N:196). Body mass index showed no impact on clinical benefit rates in the overall study sample and in the luminal cancer subset (p = 0.12 and p = 0.79, respectively), but did so in the triple negative subgroup, with higher rates in patients with body mass index ≥25 (p = 0.03). In the overall study sample, body mass index did no impact progression free or overall survival (p = 0.33 and p = 0.67, respectively). Conversely, in triple negative patients, progression free survival was significantly longer with body mass index ≥25 (6 vs 14 months, p = 0.04). In this subset, overall survival was more favorable (25 vs 19 months, p = 0.02). The impact of the molecular subtype was confirmed in multivariate models including the length of progression free survival, and number of metastatic sites (p < 0.0001). Further studies are warranted to confirm our findings in more adequately sized, ad hoc, prospective studies.",
keywords = "Bevacizumab-including regimens, BMI, first-line treatment, HER2-negative metastatic breast cancer, triple negative subtype",
author = "Laura Pizzuti and Domenico Sergi and Isabella Sperduti and Lauro, {Luigi Di} and Marco Mazzotta and Claudio Botti and Fiorentino Izzo and Luca Marchetti and Silverio Tomao and Paolo Marchetti and Clara Natoli and Antonino Grassadonia and Teresa Gamucci and Lucia Mentuccia and Emanuela Magnolfi and Angela Vaccaro and Alessandra Cassano and Ernesto Rossi and Andrea Botticelli and Valentina Sini and Sarobba, {Maria G.} and Fabbri, {Maria Agnese} and Luca Moscetti and Antonio Astone and Andrea Michelotti and {De Angelis}, Claudia and Ilaria Bertolini and Francesco Angelini and Gennaro Ciliberto and Marcello Maugeri-Sacc{\`a} and Antonio Giordano and Maddalena Barba and Patrizia Vici",
year = "2018",
month = "2",
day = "9",
doi = "10.1080/15384047.2017.1416938",
language = "English",
pages = "1--7",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",

}

TY - JOUR

T1 - Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab

AU - Pizzuti, Laura

AU - Sergi, Domenico

AU - Sperduti, Isabella

AU - Lauro, Luigi Di

AU - Mazzotta, Marco

AU - Botti, Claudio

AU - Izzo, Fiorentino

AU - Marchetti, Luca

AU - Tomao, Silverio

AU - Marchetti, Paolo

AU - Natoli, Clara

AU - Grassadonia, Antonino

AU - Gamucci, Teresa

AU - Mentuccia, Lucia

AU - Magnolfi, Emanuela

AU - Vaccaro, Angela

AU - Cassano, Alessandra

AU - Rossi, Ernesto

AU - Botticelli, Andrea

AU - Sini, Valentina

AU - Sarobba, Maria G.

AU - Fabbri, Maria Agnese

AU - Moscetti, Luca

AU - Astone, Antonio

AU - Michelotti, Andrea

AU - De Angelis, Claudia

AU - Bertolini, Ilaria

AU - Angelini, Francesco

AU - Ciliberto, Gennaro

AU - Maugeri-Saccà, Marcello

AU - Giordano, Antonio

AU - Barba, Maddalena

AU - Vici, Patrizia

PY - 2018/2/9

Y1 - 2018/2/9

N2 - The evidence emerged from the TOURANDOT trial encourages evaluating the role of anthropometric determinants on treatment outcomes in HER2-negative metastatic breast cancer patients treated with bevacizumab-including regimens. We thus analyzed data from a subgroup of these patients from a larger cohort previously assessed for treatment outcomes. Patients were included in the present analysis if body mass index values had been recorded at baseline. Clinical benefit rates, progression free survival and overall survival were assessed for the overall study population and subgroups defined upon molecular subtype. One hundred ninety six patients were included (N:196). Body mass index showed no impact on clinical benefit rates in the overall study sample and in the luminal cancer subset (p = 0.12 and p = 0.79, respectively), but did so in the triple negative subgroup, with higher rates in patients with body mass index ≥25 (p = 0.03). In the overall study sample, body mass index did no impact progression free or overall survival (p = 0.33 and p = 0.67, respectively). Conversely, in triple negative patients, progression free survival was significantly longer with body mass index ≥25 (6 vs 14 months, p = 0.04). In this subset, overall survival was more favorable (25 vs 19 months, p = 0.02). The impact of the molecular subtype was confirmed in multivariate models including the length of progression free survival, and number of metastatic sites (p < 0.0001). Further studies are warranted to confirm our findings in more adequately sized, ad hoc, prospective studies.

AB - The evidence emerged from the TOURANDOT trial encourages evaluating the role of anthropometric determinants on treatment outcomes in HER2-negative metastatic breast cancer patients treated with bevacizumab-including regimens. We thus analyzed data from a subgroup of these patients from a larger cohort previously assessed for treatment outcomes. Patients were included in the present analysis if body mass index values had been recorded at baseline. Clinical benefit rates, progression free survival and overall survival were assessed for the overall study population and subgroups defined upon molecular subtype. One hundred ninety six patients were included (N:196). Body mass index showed no impact on clinical benefit rates in the overall study sample and in the luminal cancer subset (p = 0.12 and p = 0.79, respectively), but did so in the triple negative subgroup, with higher rates in patients with body mass index ≥25 (p = 0.03). In the overall study sample, body mass index did no impact progression free or overall survival (p = 0.33 and p = 0.67, respectively). Conversely, in triple negative patients, progression free survival was significantly longer with body mass index ≥25 (6 vs 14 months, p = 0.04). In this subset, overall survival was more favorable (25 vs 19 months, p = 0.02). The impact of the molecular subtype was confirmed in multivariate models including the length of progression free survival, and number of metastatic sites (p < 0.0001). Further studies are warranted to confirm our findings in more adequately sized, ad hoc, prospective studies.

KW - Bevacizumab-including regimens

KW - BMI

KW - first-line treatment

KW - HER2-negative metastatic breast cancer

KW - triple negative subtype

UR - http://www.scopus.com/inward/record.url?scp=85042233238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042233238&partnerID=8YFLogxK

U2 - 10.1080/15384047.2017.1416938

DO - 10.1080/15384047.2017.1416938

M3 - Article

SP - 1

EP - 7

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

ER -